Xeris Biopharma Holdings Inc
NASDAQ:XERS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Xeris Biopharma Holdings Inc
NASDAQ:XERS
|
1.1B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
990.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Xeris Biopharma Holdings Inc
Glance View
Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Xeris Biopharma Holdings Inc is -5.9%, which is above its 3-year median of -33.3%.
Over the last 3 years, Xeris Biopharma Holdings Inc’s Net Margin has increased from -134.5% to -5.9%. During this period, it reached a low of -134.5% on Sep 30, 2022 and a high of -5.9% on Sep 30, 2025.
